Compare DSY & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | SCNX |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 16.2M |
| IPO Year | 2023 | 2019 |
| Metric | DSY | SCNX |
|---|---|---|
| Price | $3.60 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 17.9K | ★ 609.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.17 | $0.24 |
| 52 Week High | $19.90 | $2.60 |
| Indicator | DSY | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 23.28 |
| Support Level | $3.42 | $0.24 |
| Resistance Level | $3.69 | $0.43 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 35.34 | 7.47 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.